Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 9/20 | 0.41 |
| ▸ | DRD2 | P14416 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.41 |
| ▸ | HTR6 | P50406 | 6/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2307103 | 0.99 | HTR7 (0.41) | HTR7DRD2HTR2AHTR6NPY5R | |
| SCHEMBL13482115 | 0.97 | HTR7 (0.42) | HTR7DRD2HTR2AHTR6NPY5R | |
| Hydrochloric Acid SCHEMBL2308729 | 0.97 | HTR7 (0.41) | HTR7DRD2HTR2AHTR6NPY5R | |
| SCHEMBL13482132 | 0.91 | HTR7 (0.45) | HTR7DRD2HTR2AHTR6POLB | |
| Hydrochloric Acid SCHEMBL3184930 | 0.91 | HTR7 (0.44) | HTR7DRD2HTR2AHTR6POLB | |
| SCHEMBL13482105 | 0.89 | HTR7 (0.46) | HTR7DRD2HTR2AHTR6HTR1A | |
| SCHEMBL13482244 | 0.88 | HTR1A (0.49) | HTR7DRD2HTR2AHTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL2309173 | 0.88 | HTR7 (0.45) | HTR7DRD2HTR2AHTR6HTR1A | |
| SCHEMBL2309276 | 0.87 | KMT2A (0.40) | HTR7HTR6KMT2APOLB | |
| Hydrochloric Acid SCHEMBL2306339 | 0.87 | HTR1A (0.49) | HTR7DRD2HTR2AHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662862-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-16 | — | — | US | disclosed |
| US-7662862-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-16 | — | — | US | disclosed |
| US-20090264458-A1 | 5-HT7 RECEPTOR ANTAGONISTS | JOVER ANTONI TORRENS | 2009-10-22 | — | — | US | disclosed |
| US-20090264458-A1 | 5-HT7 RECEPTOR ANTAGONISTS | JOVER ANTONI TORRENS | 2009-10-22 | — | — | US | disclosed |
| US-7553965-B2 | Central nervous system disorders; compounds are 3-sulfonamidoalkyl 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylenes | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-06-30 | — | — | US | disclosed |
| US-7553965-B2 | Central nervous system disorders; compounds are 3-sulfonamidoalkyl 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylenes | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2009-06-30 | — | — | US | disclosed |
| US-20090036480-A1 | 5-Ht7 Receptor Antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-02-05 | — | — | US | disclosed |
| US-20090036480-A1 | 5-Ht7 Receptor Antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264458-A1 | 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR1A, HTR2B | HTR7 1/4885DRD2 98/4885HTR2A 6/4885 |
| US-20090036480-A1 | 5-Ht7 Receptor Antagonists | HTR7, HTR1A, HTR2B | HTR7 1/4885DRD2 107/4885HTR2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.